Is TNGX or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -25.75% -23.36% Aktis Oncology N/A N/A N/A

Does the media favor TNGX or AKTS?

In the previous week, Tango Therapeutics and Tango Therapeutics both had 4 articles in the media. Tango Therapeutics' average media sentiment score of 1.29 beat Aktis Oncology's score of 0.87 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, AKTS or VCYT?

Veracyte has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 137.60 -$63.73M -$0.82 N/A Veracyte $517.15M 6.70 $66.35M $1.41 30.57

Does the media favor AKTS or VCYT?

In the previous week, Veracyte had 2 more articles in the media than Aktis Oncology. MarketBeat recorded 6 mentions for Veracyte and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.87 beat Veracyte's score of 0.54 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, AKTS or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Aktis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 137.60 -$63.73M -$0.82 N/A Telix Pharmaceuticals $803.79M 4.62 -$7.12M N/A N/A

Is AKTS or TLX more profitable?

Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Telix Pharmaceuticals N/A N/A N/A

Does the media favor AKTS or TLX?

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Aktis Oncology. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.87 beat Telix Pharmaceuticals' score of 0.09 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AKTS or VKTX more profitable?

Aktis Oncology's return on equity of 0.00% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Viking Therapeutics N/A -94.56% -82.75%

Does the media favor AKTS or VKTX?

In the previous week, Viking Therapeutics had 3 more articles in the media than Aktis Oncology. MarketBeat recorded 7 mentions for Viking Therapeutics and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.87 beat Viking Therapeutics' score of 0.37 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PBLS or AKTS more profitable?

Company Net Margins Return on Equity Return on Assets Parabilis Medicines N/A N/A N/A Aktis Oncology N/A N/A N/A

Does the media prefer PBLS or AKTS?

In the previous week, Aktis Oncology had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Aktis Oncology's score of 0.87 indicating that Parabilis Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aktis Oncology (AKTS) Competitors

$16.41 -0.23 (-1.38%)

As of 12:29 PM Eastern

Compare

AKTS vs. TNGX, VCYT, TLX, VKTX, and PBLS

Should you buy Aktis Oncology stock or one of its competitors? Aktis Oncology's main competitors and comparable companies include Tango Therapeutics (TNGX), Veracyte (VCYT), Telix Pharmaceuticals (TLX), Viking Therapeutics (VKTX), and Parabilis Medicines (PBLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aktis Oncology compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Tango Therapeutics and Tango Therapeutics both had 4 articles in the media. Tango Therapeutics' average media sentiment score of 1.29 beat Aktis Oncology's score of 0.87 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Aktis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	60.06	-$101.59M	-$0.85	N/A
Aktis Oncology	$6.50M	137.60	-$63.73M	-$0.82	N/A

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aktis Oncology's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Aktis Oncology	N/A	N/A	N/A

Tango Therapeutics presently has a consensus target price of $43.46, suggesting a potential upside of 95.60%. Aktis Oncology has a consensus target price of $35.63, suggesting a potential upside of 114.09%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Summary

Aktis Oncology beats Tango Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Aktis Oncology compare to Veracyte?

Aktis Oncology (NASDAQ:AKTS) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Aktis Oncology currently has a consensus price target of $35.63, suggesting a potential upside of 114.09%. Veracyte has a consensus price target of $55.78, suggesting a potential upside of 29.38%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Aktis Oncology is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Veracyte has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	137.60	-$63.73M	-$0.82	N/A
Veracyte	$517.15M	6.70	$66.35M	$1.41	30.57

28.8% of Aktis Oncology shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Veracyte has a net margin of 20.37% compared to Aktis Oncology's net margin of 0.00%. Veracyte's return on equity of 9.26% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Veracyte	20.37%	9.26%	8.61%

In the previous week, Veracyte had 2 more articles in the media than Aktis Oncology. MarketBeat recorded 6 mentions for Veracyte and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.87 beat Veracyte's score of 0.54 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Veracyte beats Aktis Oncology on 8 of the 14 factors compared between the two stocks.

How does Aktis Oncology compare to Telix Pharmaceuticals?

Aktis Oncology (NASDAQ:AKTS) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Aktis Oncology currently has a consensus price target of $35.63, suggesting a potential upside of 114.09%. Telix Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 87.73%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Aktis Oncology is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Telix Pharmaceuticals has higher revenue and earnings than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	137.60	-$63.73M	-$0.82	N/A
Telix Pharmaceuticals	$803.79M	4.62	-$7.12M	N/A	N/A

28.8% of Aktis Oncology shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Aktis Oncology. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.87 beat Telix Pharmaceuticals' score of 0.09 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aktis Oncology beats Telix Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Aktis Oncology compare to Viking Therapeutics?

Aktis Oncology (NASDAQ:AKTS) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aktis Oncology currently has a consensus price target of $35.63, suggesting a potential upside of 114.09%. Viking Therapeutics has a consensus price target of $99.44, suggesting a potential upside of 273.15%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Aktis Oncology has higher revenue and earnings than Viking Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	137.60	-$63.73M	-$0.82	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Aktis Oncology's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Viking Therapeutics	N/A	-94.56%	-82.75%

In the previous week, Viking Therapeutics had 3 more articles in the media than Aktis Oncology. MarketBeat recorded 7 mentions for Viking Therapeutics and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.87 beat Viking Therapeutics' score of 0.37 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aktis Oncology beats Viking Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Aktis Oncology compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Parabilis Medicines presently has a consensus price target of $41.67, suggesting a potential upside of 55.18%. Aktis Oncology has a consensus price target of $35.63, suggesting a potential upside of 114.09%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

In the previous week, Aktis Oncology had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Aktis Oncology's score of 0.87 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.8% of Aktis Oncology shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aktis Oncology has higher revenue and earnings than Parabilis Medicines. Aktis Oncology is trading at a lower price-to-earnings ratio than Parabilis Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	-$145.89M	-$2.13	N/A
Aktis Oncology	$6.50M	137.60	-$63.73M	-$0.82	N/A

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Aktis Oncology	N/A	N/A	N/A

Summary

Aktis Oncology beats Parabilis Medicines on 8 of the 9 factors compared between the two stocks.

Get Aktis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTS vs. The Competition

Export

Metric	Aktis Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$882.04M	$3.89B	$7.28B	$13.01B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-20.01	12.99	275.44	25.42
Price / Sales	135.70	1,141.69	559.80	78.81
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-5.68	16.88	10.66	5.96
Net Income	-$63.73M	-$22.65M	$3.50B	$380.62M
7 Day Performance	-8.83%	-5.64%	-3.65%	-3.75%
1 Month Performance	-29.18%	-13.53%	-8.06%	-6.62%
1 Year Performance	N/A	6.87%	2.58%	-4.38%

Aktis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTS Aktis Oncology	2.4093 of 5 stars	$16.41 -1.4%	$35.63 +117.1%	N/A	$882.04M	$6.50M	N/A	79
TNGX Tango Therapeutics	2.1418 of 5 stars	$23.08 -0.7%	$43.46 +88.3%	+162.3%	$3.89B	$62.38M	N/A	137	Positive News
VCYT Veracyte	4.2495 of 5 stars	$47.67 +4.1%	$55.78 +17.0%	+26.5%	$3.83B	$517.15M	33.81	755
TLX Telix Pharmaceuticals	4.3798 of 5 stars	$10.88 +3.1%	$20.50 +88.4%	+14.5%	$3.70B	$803.79M	N/A	1,184
VKTX Viking Therapeutics	3.4871 of 5 stars	$29.28 -2.2%	$99.67 +240.4%	-21.4%	$3.69B	N/A	N/A	65	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aktis Oncology (AKTS) Competitors

AKTS vs. TNGX, VCYT, TLX, VKTX, and PBLS

How does Aktis Oncology compare to Tango Therapeutics?

Summary

How does Aktis Oncology compare to Veracyte?

Summary

How does Aktis Oncology compare to Telix Pharmaceuticals?

Summary

How does Aktis Oncology compare to Viking Therapeutics?

Summary

How does Aktis Oncology compare to Parabilis Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aktis Oncology (AKTS) Competitors

AKTS vs. TNGX, VCYT, TLX, VKTX, and PBLS

How does Aktis Oncology compare to Tango Therapeutics?

Does the media favor TNGX or AKTS?

Which has stronger earnings and valuation, TNGX or AKTS?

Do insiders and institutionals hold more shares of TNGX or AKTS?

Is TNGX or AKTS more profitable?

Do analysts prefer TNGX or AKTS?

Summary

How does Aktis Oncology compare to Veracyte?

Do analysts recommend AKTS or VCYT?

Which has higher valuation & earnings, AKTS or VCYT?

Do insiders & institutionals hold more shares of AKTS or VCYT?

Is AKTS or VCYT more profitable?

Does the media favor AKTS or VCYT?

Summary

How does Aktis Oncology compare to Telix Pharmaceuticals?

Do analysts recommend AKTS or TLX?

Which has higher valuation & earnings, AKTS or TLX?

Do insiders & institutionals hold more shares of AKTS or TLX?

Is AKTS or TLX more profitable?

Does the media favor AKTS or TLX?

Summary

How does Aktis Oncology compare to Viking Therapeutics?

Do institutionals & insiders hold more shares of AKTS or VKTX?

Do analysts recommend AKTS or VKTX?

Which has stronger earnings & valuation, AKTS or VKTX?

Is AKTS or VKTX more profitable?

Does the media favor AKTS or VKTX?

Summary

How does Aktis Oncology compare to Parabilis Medicines?

Do analysts recommend PBLS or AKTS?

Does the media prefer PBLS or AKTS?

Do institutionals & insiders hold more shares of PBLS or AKTS?

Which has preferable valuation and earnings, PBLS or AKTS?

Is PBLS or AKTS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools